CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025Successful Rights Offering and exercise of Series